Cramer’s Stock Picks at the Market Top
24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.
Headquartered in Danbury, CT Fiscal year ends December NASDAQ: MNKD mannkindcorp.com
MannKind Corporation is a biopharmaceutical company focused on transforming chronic disease care through innovative drug-device combination therapies for cardiometabolic and orphan lung diseases. Its commercial portfolio includes Afrezza (inhaled insulin for diabetes, now approved for adults and pediatric patients ages 6+), Furoscix (subcutaneous furosemide injection for edema in heart failure and chronic kidney disease, including the newly approved ReadyFlow autoinjector), and V-Go (a wearable insulin delivery device). MannKind also generates significant revenue from collaborations with United Therapeutics, including manufacturing and royalties related to Tyvaso DPI for pulmonary hypertension. The company's development pipeline includes MNKD-201 (nintedanib dry powder inhaler for idiopathic pulmonary fibrosis, currently in Phase 2) and MNKD-1501 (ralinepag DPI for pulmonary arterial hypertension, approaching IND filing). MannKind leverages its proprietary Technosphere drug-device platform to deliver therapies via inhalation, targeting improved patient compliance and outcomes. Updated
24/7 Wall St. takes a look at famed market personality Jim Cramer’s latest buy and sell recommendations and overall analysis.
The July 31 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The July 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The June 30 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The June 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The May 29 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The May 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks was mixed.
The April 30 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks increased.
The April 15 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The March 31 short interest data has been compared with the previous report, and short interest in these selected biotech stocks shrank.
The March 13 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The February 28 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The February 14 short interest data has been compared with the previous report, and short interest moves in these selected biotech stocks were mixed.
The January 31 data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
The January 15 short interest data has been compared with the previous report, and short interest in most of these selected biotech stocks decreased.
MannKind Corporation is a biopharmaceutical company focused on transforming chronic disease care through innovative drug-device combination therapies for cardiometabolic and orphan lung diseases.
The Wall Street consensus 12-month price target for MNKD is $7.97.